PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.
PD‐L1 status
gender medicine
genetic aberrations
non‐small cell lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
revised:
21
04
2024
received:
05
02
2024
accepted:
01
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
Programmed cell death-ligand 1 (PD-L1) expression is a well-established biomarker for predicting responses to immune checkpoint inhibitors and certain targeted therapies. As a result, treatment strategies for patients vary based on their PD-L1 expression status. Understanding the clinical features of patients with distinct PD-L1 levels is crucial for personalized treatment approaches. Demographic and clinicopathological characteristics of 227 patients (54% male, mean age 67 ± 9.9 years) newly diagnosed with non-small-cell lung cancer (NSCLC) between April 2020 and December 2022 were retrospectively compared among three groups based on the PD-L1 expression: PD-L1 Tumor Proportion Score (TPS) negative, 1-50%, and ≥50%. Logistic regression analysis was performed to evaluate predictors for high PD-L1 expression ≥50%. PD-L1 expression levels were distributed as follows: negative in 29% of patients, between 1% and 50% in 41%, and greater than 50% (high) in 29%. In comparison to negative PD-L1 expression, low and high PD-L1 expression was associated with female sex (32.9% vs. 52.7% vs. 50.7%, p = 0.031), with the absence of epidermal growth factor receptor (EGFR) mutations (83.6% vs. 91.1% vs. 98.1% p = 0.029), and with the absence of ERBB2 (HER2) tyrosine kinase mutations (90.9% vs. 100% vs. 98.1% p = 0.007), respectively. Age, smoking status, histological subtype, and disease stage showed no significant differences among the three patient groups. In the univariate logistic regression, EGFR mutation appeared to be the only predictor for PD-L1 expression, although it did not reach statistical significance (p = 0.06). Although sex and genomic alterations are associated with PD-L1 expression in patients with NSCLC, no clinical characteristics seem to predict PD-L1 expression significantly.
Sections du résumé
BACKGROUND
BACKGROUND
Programmed cell death-ligand 1 (PD-L1) expression is a well-established biomarker for predicting responses to immune checkpoint inhibitors and certain targeted therapies. As a result, treatment strategies for patients vary based on their PD-L1 expression status. Understanding the clinical features of patients with distinct PD-L1 levels is crucial for personalized treatment approaches.
METHODS
METHODS
Demographic and clinicopathological characteristics of 227 patients (54% male, mean age 67 ± 9.9 years) newly diagnosed with non-small-cell lung cancer (NSCLC) between April 2020 and December 2022 were retrospectively compared among three groups based on the PD-L1 expression: PD-L1 Tumor Proportion Score (TPS) negative, 1-50%, and ≥50%. Logistic regression analysis was performed to evaluate predictors for high PD-L1 expression ≥50%.
RESULTS
RESULTS
PD-L1 expression levels were distributed as follows: negative in 29% of patients, between 1% and 50% in 41%, and greater than 50% (high) in 29%. In comparison to negative PD-L1 expression, low and high PD-L1 expression was associated with female sex (32.9% vs. 52.7% vs. 50.7%, p = 0.031), with the absence of epidermal growth factor receptor (EGFR) mutations (83.6% vs. 91.1% vs. 98.1% p = 0.029), and with the absence of ERBB2 (HER2) tyrosine kinase mutations (90.9% vs. 100% vs. 98.1% p = 0.007), respectively. Age, smoking status, histological subtype, and disease stage showed no significant differences among the three patient groups. In the univariate logistic regression, EGFR mutation appeared to be the only predictor for PD-L1 expression, although it did not reach statistical significance (p = 0.06).
CONCLUSION
CONCLUSIONS
Although sex and genomic alterations are associated with PD-L1 expression in patients with NSCLC, no clinical characteristics seem to predict PD-L1 expression significantly.
Identifiants
pubmed: 38860475
doi: 10.1111/1759-7714.15336
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd.
Références
Malvezzi M, Santucci C, Boffetta P, Collatuzzo G, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2023 with focus on lung cancer. Ann Oncol. 2023;34(4):410–419. https://doi.org/10.1016/j.annonc.2023.01.010
Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. ESMO guidelines committee. Metastatic non‐small‐cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27(suppl 5):v1–v27. https://doi.org/10.1093/annonc/mdw326
Erdmann F, Spix C, Katalinic A, Christ M, Folkerts J, Hansmann J, Kranzhöfer K, Kunz B, Manegold K, Penzkofer A, Treml K Krebs in Deutschland für 2017/2018. Berlin: Robert Koch Institut; 2021. https://doi.org/10.25646/8353
Reck M, Rodríguez‐Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med. 2016;375:1823–1833. https://doi.org/10.1056/NEJMoa1606774
Putzu C, Canova S, Paliogiannis P, Lobrano R, Sala L, Cortinovis DL, et al. Duration of immunotherapy in non‐small cell lung cancer survivors: a lifelong commitment? Cancers (Basel). 2023;15(3):689. https://doi.org/10.3390/cancers15030689
Walia A, Prasad V. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC. J Cancer Res Clin Oncol. 2023;149(11):9513–9515. https://doi.org/10.1007/s00432-023-04749-4
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five‐year overall survival for patients with advanced non‐small‐cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE‐001 study. J Clin Oncol. 2019;37(28):2518–2527. https://doi.org/10.1200/JCO.19.00934
Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, et al. PD‐L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR‐mutant non‐small cell lung cancer patients. Sci Rep. 2022;12(1):9753. https://doi.org/10.1038/s41598-022-13102-7
Lamberti G, Sisi M, Andrini E, Palladini A, Giunchi F, Lollini PL, et al. The mechanisms of PD‐L1 regulation in non‐small‐cell lung cancer (NSCLC): which are the involved players? Cancers (Basel). 2020;12(11):3129. https://doi.org/10.3390/cancers12113129
Evans M, O'Sullivan B, Hughes F, Mullis T, Smith M, Trim N, et al. The Clinicopathological and molecular associations of PD‐L1 expression in non‐small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay. Pathol Oncol Res. 2020;26(1):79–89. https://doi.org/10.1007/s12253-018-0469-6
Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Glatzel‐Plucinska N, Grzegrzolka J, et al. Role of PD‐L1 expression in non‐small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20:824. https://doi.org/10.3390/ijms20040824
Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene‐specific differences in tumor mutational burden, PD‐L1 expression, and outcomes from immunotherapy in non‐small cell lung cancer. J Immunother Cancer. 2021;9(8):e002891. https://doi.org/10.1136/jitc-2021-002891
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta‐analysis. Lancet Oncol. 2018;19(6):737–746. https://doi.org/10.1016/S1470-2045(18)30261-4
Klein S, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–638.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–1570.
Conforti F, Pala L, Pagan E, Corti C, Bagnardi V, Queirolo P, et al. Sex‐based differences in response to anti‐PD‐1 or PD‐L1 treatment in patients with non‐small‐cell lung cancer expressing high PD‐L1 levels. A systematic review and meta‐analysis of randomized clinical trials. ESMO Open. 2021;6(5):100251. https://doi.org/10.1016/j.esmoop.2021.100251
Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, et al. PD‐L1 expression in lung cancer and its correlation with driver mutations: a meta‐analysis. Sci Rep. 2017;7(1):10255. https://doi.org/10.1038/s41598-017-10925-7
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD‐L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–215. https://doi.org/10.1016/j.lungcan.2017.08.005
Chen Q, Fu YY, Yue QN, Wu Q, Tang Y, Wang WY, et al. Distribution of PD‐L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non‐small cell lung cancer. Int J Clin Exp Pathol. 2019;12(3):774–786.
Mansour MSI, Malmros K, Mager U, Ericson Lindquist K, Hejny K, Holmgren B, et al. PD‐L1 expression in non‐small cell lung cancer specimens: association with clinicopathological factors and molecular alterations. Int J Mol Sci. 2022;23(9):4517. https://doi.org/10.3390/ijms23094517
Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, et al. Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer. 2022;13(1):38–47. https://doi.org/10.1111/1759-7714.14216
Zheng Q, Huang Y, Zeng X, Chen X, Shao S, Jin Y, et al. Clinicopathological and molecular characteristics associated with PD‐L1 expression in non‐small cell lung cancer: a large‐scale, multi‐center, real‐world study in China. J Cancer Res Clin Oncol. 2021;147(5):1547–1556. https://doi.org/10.1007/s00432-020-03444-y
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, et al. Clinical significance of PD‐L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 2016;11(11):1879–1890. https://doi.org/10.1016/j.jtho.2016.06.006
Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD‐L1 and EGFR status and the prognostic value of PD‐L1 in advanced non‐small cell lung cancer patients treated with EGFR‐TKIs. Oncotarget. 2015;6(16):14209–14219. https://doi.org/10.18632/oncotarget.3694
Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, et al. PD‐1 and PD‐L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10(8):e0136023. https://doi.org/10.1371/journal.pone.0136023
Yang X, Jiang L, Jin Y, Li P, Hou Y, Yun J, et al. PD‐L1 expression in Chinese patients with advanced non‐small cell lung cancer (NSCLC): a multi‐center retrospective observational study. J Cancer. 2021;12(24):7390–7398. https://doi.org/10.7150/jca.63003
Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD‐L1) expression in nonsquamous non‐small‐cell lung cancer. Ann Oncol. 2020;31(6):807–814. https://doi.org/10.1016/j.annonc.2020.02.017
Uruga H, Bozkurtlar E, Huynh TG, Muzikansky A, Goto Y, Gomez‐Caraballo M, et al. Programmed cell death ligand (PD‐L1) expression in stage II and III lung adenocarcinomas and nodal metastases. J Thorac Oncol. 2017;12(3):458–466. https://doi.org/10.1016/j.jtho.2016.10.015
Song P, Guo L, Li W, Zhang F, Ying J, Gao S. Clinicopathologic correlation with expression of PD‐L1 on both tumor cells and tumor‐infiltrating immune cells in patients with non‐small cell lung cancer. J Immunother. 2019;42(1):23–28. https://doi.org/10.1097/CJI.0000000000000249
Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD‐1 and its ligands, PD‐L1 and PD‐L2, in smokers and never smokers with KRAS‐mutant lung cancer. J Thorac Oncol. 2015;10:1726–1735.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer. Science. 2015;348(6230):124–128. https://doi.org/10.1126/science.aaa1348
Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, et al. The aryl hydrocarbon receptor mediates tobacco‐induced PD‐L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10:1125.
Kwok HH, Gao B, Chan KH, Ip MS, Minna JD, Lam DC. Nicotinic acetylcholine receptor subunit α7 mediates cigarette smoke‐induced PD‐L1 expression in human bronchial epithelial cells. Cancers (Basel). 2021;13(21):5345. https://doi.org/10.3390/cancers13215345
Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, et al. Impact of patient characteristics, prior therapy, and sample type on tumor cell programmed cell death ligand 1 expression in patients with advanced NSCLC screened for the ATLANTIC study. J Thorac Oncol. 2019.;14(8):1390–1399.
Conway EM, Pikor LA, Kung SH, Hamilton MJ, Lam S, Lam WL, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193(2):116–130. https://doi.org/10.1164/rccm.201508-1545CI
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD‐L1 checkpoint. Immunity. 2018;48(3):434–452. https://doi.org/10.1016/j.immuni.2018.03.014
Chen K, Pan G, Cheng G, Zhang F, Xu Y, Huang Z, et al. Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions. J ThoracCancer. 2021;12(2):218–226. https://doi.org/10.1111/1759-7714.13748
Chu CH, Huang YH, Lee PH, Hsu KH, Chen KC, Su KY, et al. Various impacts of driver mutations on the PD‐L1 expression of NSCLC. PLoS One. 2022;17(8):e0273207. https://doi.org/10.1371/journal.pone.0273207
Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD‐L1) expression in patients with non‐small cell lung cancer: a meta‐analysis. J Thorac Dis. 2015;7(3):462–470. https://doi.org/10.3978/j.issn.2072-1439.2015.02.13
Zhao Y, Shi F, Zhou Q, Li Y, Wu J, Wang R, et al. Prognostic significance of PD‐L1 in advanced non‐small cell lung carcinoma. Medicine (Baltimore). 2020;99(45):e23172. https://doi.org/10.1097/MD.0000000000023172
Tuminello S, Sikavi D, Veluswamy R, Gamarra C, Lieberman‐Cribbin W, Flores R, et al. PD‐L1 as a prognostic biomarker in surgically resectable non‐small cell lung cancer: a meta‐analysis. Transl Lung Cancer Res. 2020;9(4):1343–1360. https://doi.org/10.21037/tlcr-19-638
Garinet S, Wang P, Mansuet‐Lupo A, Fournel L, Wislez M, Blons H. Updated prognostic factors in localized NSCLC. Cancers (Basel). 2022;14(6):1400. https://doi.org/10.3390/cancers14061400
Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti‐PD‐1/PD‐L1 therapy in NSCLC. Exp Hematol Oncol. 2021;10(1):18. https://doi.org/10.1186/s40164-021-00211-8
Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double‐strand break repair pathway regulates PD‐L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. https://doi.org/10.1038/s41467-017-01883-9
Gandhi L, Rodríguez‐Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. https://doi.org/10.1056/NEJMoa1801005
Gao Y, Sun X, Hou Y, Zhang M, Tan W, Zhang Y, et al. Efficacy and safety of immunoradiotherapy for advanced non‐small cell lung cancer: a retrospective comparative cohort study. J Thorac Dis. 2023;15(6):3182–3196. https://doi.org/10.21037/jtd-22-1685
Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, et al. Expression of programmed death ligand‐1 on tumor cells varies pre and post chemotherapy in non‐small cell lung cancer. Sci Rep. 2016;6:20090. https://doi.org/10.1038/srep20090 Erratum in: Sci Rep 2016;6:23850. Yanhuang, [corrected to Huang, Yan].
Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, et al. Chemotherapy treatment is associated with altered PD‐L1 expression in lung cancer patients. J Cancer Res Clin Oncol. 2018;144(7):1219–1226. https://doi.org/10.1007/s00432-018-2642-4
Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, et al. EBUS‐TBNA as a promising method for the evaluation of tumor PD‐L1 expression in lung cancer. Clin Lung Cancer. 2017;18(5):527–534.e1.
Gompelmann D, Sinn K, Brugger J, Bernitzky D, Mosleh B, Prosch H, et al. Correlation of PD‐L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. J Cancer Res Clin Oncol. 2023;149(5):1747–1754.
Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, et al. Clinical and molecular correlates of PD‐L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599–608. https://doi.org/10.1016/j.annonc.2020.01.065 Epub 2020 Feb 6. PMID: 32178965; PMCID: PMC7523592.
Dodson A, Parry S, Lissenberg‐Witte B, Haragan A, Allen D, O'Grady A, et al. External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different. J Pathol Clin Res. 2020;6(2):138–145. https://doi.org/10.1002/cjp2.153